Cubist Pharmaceuticals, Inc. Reports GAAP Diluted Net Income of $1.82 Per Share in Fourth Quarter 2008 and GAAP Diluted Net Income of $2.56 Per Share for Full Year 2008

LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today reported results for the fourth quarter and year ended December 31, 2008. Total net revenues for the fourth quarter of 2008 increased 53% to $131.2 million from $85.6 million in the fourth quarter of 2007. This increase was attributable primarily to Cubist’s net sales of CUBICIN® (daptomycin for injection) in the United States, which increased 43% to $120.1 million in the fourth quarter of 2008 from $83.9 million in the fourth quarter of 2007.